Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 positive||Advanced Solid Tumor||predicted - sensitive||Epertinib||Phase I||Actionable||In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).||detail... 25434923|
|PubMed Id||Reference Title||Details|
|A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.||Full reference...|
|(25434923)||Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.||Full reference...|